Tecentriq and bevacizumab (atezolizumab & bevacizumab)

pCPA File Number: 21390
Negotiation Status:
Active Negotiation
Indication(s):
Hepatocellular Carcinoma (HCC)
Sponsor/Manufacturer:
HOFFMANN-LA ROCHE LIMITED
CADTH Project Number:
pCODR 10217
pCPA Engagement Letter Issued:
Negotiation Process Concluded:
Not Applicable